Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
Nizar J. Bahlis, Heather J. Sutherland, Darrell White, et al.
Blood (2018) Vol. 132, Iss. 24, pp. 2546-2554
Open Access | Times Cited: 128

Showing 1-25 of 128 citing articles:

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani, et al.
The Lancet (2021) Vol. 398, Iss. 10297, pp. 314-324
Closed Access | Times Cited: 1175
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Thierry Façon, Shaji Kumar, Torben Plesner, et al.
New England Journal of Medicine (2019) Vol. 380, Iss. 22, pp. 2104-2115
Open Access | Times Cited: 840
NF‐κB signaling in inflammation and cancer
Tao Zhang, Chao Ma, Zhiqiang Zhang, et al.
MedComm (2021) Vol. 2, Iss. 4, pp. 618-653
Open Access | Times Cited: 284
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
Sebastian Grosicki, Maryana Simonova, Ivan Špıčka, et al.
The Lancet (2020) Vol. 396, Iss. 10262, pp. 1563-1573
Open Access | Times Cited: 257
The nuclear export protein XPO1 — from biology to targeted therapy
Asfar S. Azmi, Md. Hafiz Uddin, Ramzi M. Mohammad
Nature Reviews Clinical Oncology (2020) Vol. 18, Iss. 3, pp. 152-169
Closed Access | Times Cited: 197
XPO1-dependent nuclear export as a target for cancer therapy
Nancy G. Azizian, Yulin Li
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 186
Relapsed refractory multiple myeloma: a comprehensive overview
Abdul Hamid Bazarbachi, Rama Al Hamed, Florent Malard, et al.
Leukemia (2019) Vol. 33, Iss. 10, pp. 2343-2357
Closed Access | Times Cited: 133
Treatment Options for Triple-class Refractory Multiple Myeloma
Joseph Mıkhael
Clinical Lymphoma Myeloma & Leukemia (2019) Vol. 20, Iss. 1, pp. 1-7
Open Access | Times Cited: 107
Selinexor: First Global Approval
Yahiya Y. Syed
Drugs (2019) Vol. 79, Iss. 13, pp. 1485-1494
Closed Access | Times Cited: 104
Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
Justin Taylor, Maria Sendino, Alexander N. Gorelick, et al.
Cancer Discovery (2019) Vol. 9, Iss. 10, pp. 1452-1467
Open Access | Times Cited: 88
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
Maria Gavriatopoulou, Ajai Chari, Christine Chen, et al.
Leukemia (2020) Vol. 34, Iss. 9, pp. 2430-2440
Open Access | Times Cited: 73
Emerging agents and regimens for multiple myeloma
Yang Yang, Yi Li, Huiyao Gu, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 71
Multiple Myeloma Therapy: Emerging Trends and Challenges
Danai Dima, Dongxu Jiang, Divya Jyoti Singh, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4082-4082
Open Access | Times Cited: 43
Controlling the Gatekeeper: Therapeutic Targeting of Nuclear Transport
Friederike Katharina Kosyna, Reinhard Depping
Cells (2018) Vol. 7, Iss. 11, pp. 221-221
Open Access | Times Cited: 75
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
Andrzej Jakubowiak, Jagoda Jasielec, Cara A. Rosenbaum, et al.
British Journal of Haematology (2019) Vol. 186, Iss. 4, pp. 549-560
Open Access | Times Cited: 66
Targeting nuclear import and export in hematological malignancies
Boaz Nachmias, Aaron D. Schimmer
Leukemia (2020) Vol. 34, Iss. 11, pp. 2875-2886
Open Access | Times Cited: 64
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Philippe Moreau, Elena Zamagni, María‐Victoria Mateos
Blood Cancer Journal (2019) Vol. 9, Iss. 4
Open Access | Times Cited: 59
Selinexor for the treatment of multiple myeloma
Klaus Podar, Jatin J. Shah, Ajai Chari, et al.
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 4, pp. 399-408
Closed Access | Times Cited: 57
Selinexor in relapsed/refractory multiple myeloma
Joshua Richter, Deepu Madduri, Shambavi Richard, et al.
Therapeutic Advances in Hematology (2020) Vol. 11
Open Access | Times Cited: 52
Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms
Suresh Kumar Balasubramanian, Asfar S. Azmi, Jaroslaw P. Maciejewski
Leukemia (2022) Vol. 36, Iss. 3, pp. 601-612
Open Access | Times Cited: 30
Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications.
Mohammad Alwahsh, Joviana Farhat, Shahd Talhouni, et al.
PubMed (2023) Vol. 22, pp. 146-168
Closed Access | Times Cited: 18
Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies
Xinping Cao, Xin Jin, Xiaomei Zhang, et al.
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 3, pp. 184-211
Open Access | Times Cited: 16
Selinexor: Targeting a novel pathway in multiple myeloma
Clifton C. Mo, Andrew J. Yee, Shonali Midha, et al.
eJHaem (2023) Vol. 4, Iss. 3, pp. 792-810
Open Access | Times Cited: 16
Treatment of relapsed multiple myeloma: Evidence-based recommendations
Ceren Durer, Seren Durer, Sarah Lee, et al.
Blood Reviews (2019) Vol. 39, pp. 100616-100616
Closed Access | Times Cited: 52
New drug approvals for 2019: Synthesis and clinical applications
Shuo Yuan, Bin Yu, Hong‐Min Liu
European Journal of Medicinal Chemistry (2020) Vol. 205, pp. 112667-112667
Closed Access | Times Cited: 49
Page 1 - Next Page

Scroll to top